Cell and Gene Therapy Catapult enters Japanese collaboration
The UK government-backed Cell and Gene Therapy Catapult (CGT Catapult) today announced it has signed a Memorandum of Understanding (MoU) with the Japanese Society for Regenerative Medicine (JSRM).
This agreement between the CGT Catapult and JSRM, the largest society for regenerative medicine in the world, aims to advance regenerative medicine and cell and gene therapies in both the UK and Japan.
Through this MoU, JSRM and the CGT Catapult aim to advance their individual and common missions by promoting collaboration to facilitate activities by enterprises and academic institutions of both regions in the field of regenerative medicine and cell and gene therapies. The organizations will also share information encompassing technologies, policies, legal issues and assist one another in sponsoring and hosting meetings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze